James Hollingshead Sells 600 Shares of ResMed Inc. (RMD) Stock
ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 600 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $84.96, for a total value of $50,976.00. Following the completion of the sale, the insider now directly owns 62,602 shares of the company’s stock, valued at $5,318,665.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
James Hollingshead also recently made the following trade(s):
- On Monday, November 20th, James Hollingshead sold 7,019 shares of ResMed stock. The shares were sold at an average price of $84.16, for a total value of $590,719.04.
ResMed Inc. (NYSE:RMD) traded up $0.89 on Thursday, reaching $86.42. The company’s stock had a trading volume of 481,300 shares, compared to its average volume of 404,850. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50. The stock has a market cap of $12,137.04, a P/E ratio of 34.99, a PEG ratio of 1.88 and a beta of 0.79. ResMed Inc. has a 12-month low of $61.63 and a 12-month high of $87.81.
The firm also recently announced a quarterly dividend, which was paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th were given a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a yield of 1.62%. The ex-dividend date of this dividend was Wednesday, November 8th. ResMed’s payout ratio is 56.68%.
RMD has been the subject of several research reports. Zacks Investment Research raised ResMed from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a report on Thursday, October 12th. BMO Capital Markets upped their price objective on ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a research note on Friday, October 27th. JPMorgan Chase & Co. upped their price objective on ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a research note on Monday, October 30th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a research note on Friday, September 8th. Finally, Jefferies Group reaffirmed a “sell” rating and set a $56.00 price objective on shares of ResMed in a research note on Thursday, October 12th. Five investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $68.71.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in shares of ResMed by 38.2% in the 2nd quarter. FMR LLC now owns 5,542,582 shares of the medical equipment provider’s stock worth $431,601,000 after acquiring an additional 1,531,772 shares during the period. Koch Industries Inc. grew its holdings in shares of ResMed by 17,065.2% in the 2nd quarter. Koch Industries Inc. now owns 985,796 shares of the medical equipment provider’s stock worth $973,000 after acquiring an additional 980,053 shares during the period. BlackRock Inc. grew its holdings in shares of ResMed by 6.8% in the 2nd quarter. BlackRock Inc. now owns 14,240,077 shares of the medical equipment provider’s stock worth $1,108,877,000 after acquiring an additional 904,939 shares during the period. Vanguard Group Inc. grew its holdings in shares of ResMed by 3.3% in the 2nd quarter. Vanguard Group Inc. now owns 11,914,671 shares of the medical equipment provider’s stock worth $927,797,000 after acquiring an additional 378,964 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of ResMed by 47.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 660,980 shares of the medical equipment provider’s stock worth $50,870,000 after acquiring an additional 214,122 shares during the period. Institutional investors own 61.85% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “James Hollingshead Sells 600 Shares of ResMed Inc. (RMD) Stock” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/04/james-hollingshead-sells-600-shares-of-resmed-inc-rmd-stock.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.